Conference Coverage

Neither perioperative aspirin nor clonidine prevents MI

View on the News

Complex mechanisms underlie perioperative MI

Myriad, and sometimes opposing, mechanisms contribute to perioperative MI, including excess bleeding, dramatic fluid shifts, unrelenting tachycardia, myocardial stress with fixed coronary obstruction, profound hypo- or hypertension, coronary plaque rupture, and coronary spasm, said Dr. Prashant Vaishnava and Dr. Kim A. Eagle.

So it shouldn’t be surprising that a medical therapy aimed at one of these mechanisms may actually augment a different mechanism, and end up raising MI risk. "Aspirin may reduce coronary thrombosis at the expense of excess bleeding; clonidine may reduce hypertensive swings only to be countered by clinically important hypotension," they noted.

On balance, the POISE-2 results provide cogent evidence against the use of either perioperative aspirin or clonidine.

Dr. Vaishnava and Dr. Eagle are at the Samuel and Jean A. Frankel Cardiovascular Center at the University of Michigan Health System, Ann Arbor. They reported no potential conflicts of interest. These remarks were taken from their editorial accompanying the POISE-2 trial reports (New Engl. J. Med. 2014 March 31 [doi:10.1056/NEJMe1402976]).


 

FROM ACC 14

Similarly, it is not known why clonidine failed to be protective, but the investigators offered two possible reasons. First, the drug induced hypotension, which raises the risk of perioperative MI. And second, it also induced bradycardia, which may be a proxy for an overall adverse effect on heart rate control; this also can increase the risk of perioperative MI, they said.

The POISE-2 trial was supported by the Canadian Institutes of Health Research, the National Health and Medical Research Council of Australia, and the Spanish Ministry of Health and Social Policy. Bayer Pharma provided the aspirin used in the study, and Boehringer Ingelheim provided the clonidine and some funding. Dr. Devereaux reported ties to Abbott, Bayer Pharma, Boehringer Ingelheim, Covidien, Roche, and Stryker and; some of his associates reported ties to several industry sources.

Pages

Recommended Reading

First U.S. TAVR experience fares well post-market
MDedge Surgery
Mitral valve repair no better than replacement
MDedge Surgery
Abrupt increase noted in LVAD thrombosis
MDedge Surgery
Drug-eluting stent edges drug-eluting balloon
MDedge Surgery
First-in-man bioengineered graft proves enduring for vascular access
MDedge Surgery
Routinely screen relatives when thoracic aortic aneurysm disease presents before age 60
MDedge Surgery
Ten-year outcomes for ablation in atrial fibrillation impressive
MDedge Surgery
Anatomy’s role is elusive in carotid stenting risk
MDedge Surgery
Wait! Put elective surgery on hold after stent placement
MDedge Surgery
TAVR: More procedural success with balloon-expandable valves
MDedge Surgery